Affibody’s vision is to be a leading player in the emerging field of personalized medicine within oncology, and a preferred partner and provider of high-quality biotechnology products. Affibody uses innovative protein-engineering technologies for the development of affinity ligands. Based on its proprietary technology platform, Affibody is developing a unique oncology pipeline, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. 
  • Sector: Healthcare
  • Status: Private
  • Geographic Market: Europe
  • Investment Year: 2000
  • Board Representation: Jakob Lindberg

Visit the company’s website.